Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Biotechnology
- Diagnostic
- Disease
- Diagnostic Substances
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 4269
License Grant
University hereby grants to Licensee an exclusive, worldwide License under Licensor’s rights including the right to grant subLicenses, to the Licensed Patent Rights to develop, and commercialize Licensed Products in the territory, in all fields of use.
License Property
Licensed Patent Rights
USSN 61/484330, filed May 10, 2011, entitled Hairy Cell Leukemia Biomarkers and Methods of Using Same.
Field of Use
Hairy cell leukemia (HCL) is a hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a sub-type of chronic lymphoid leukemia. HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis. The disease was formally named leukemic reticuloendotheliosis and its common name is derived from the 'hairy' appearance of the malignant B cells under a microscope.
The present invention provides, in part, a method of diagnosing hairy cell leukemia in a subject in need thereof including obtaining a biological sample from the subject and assessing the presence or absence of a BRAF mutation in the sample, wherein the presence of the BRAF mutation indicates that the subject is suffering from hairy cell leukemia. [0006] The method can further include comparing the presence, absence, or amount of the BRAF mutation in the biological sample with the presence, absence, or amount of the BRAF mutation determined in a biological sample from a subject not suffering from hairy cell leukemia or symptoms thereof. The method can be used to distinguish hairy cell leukemia cells from other forms of malignant lymphoma.
IPSCIO Record ID: 29194
License Grant
The Licensor, an University, granted a worldwide, exclusive license to the Licensee for patents and technology in the field.
License Property
License Patents European Patent No. 0636171 issued 6/7/00, Patent No.6,403,326 issued 6/11/02 and its continuation, U.S. Patent number 6,339,143 issued January 15, 2002 and certain Antibodies and Cell Lines.
Field of Use
Therapeutic Subfield of cancer therapy (active and passive immunotherapy) in humans and non-humans and fertility control in non-humans.
The Animal Subfield shall include all therapeutic treatment in non-humans.
The Diagnostic Subfield shall include all diagnostics in humans and non-humans.
IPSCIO Record ID: 7179
License Grant
Licensor, two Italian individuals, grants to Italian Licensee an exclusive license (even as to Licensor), including the right to grant sublicenses under the Licensed Patent Rights and Licensed Technology.
License Property
Licensed Patent Rights
USSN 61/540618, filed September 29, 2011, entitled Mutations and chronic lymphoblastic leukemia.
The findings have been published in the Dec 22 issue of Blood, the journal of the American Society of Hematology, in an article titled Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia association with progression and fludarabine-refractoriness (Rossi D. et al., Blood 1186904-6908, 2011). A US patent application is pending.
Field of Use
SAN DIEGO, Jan. 3, 2012 /PRNewswire/ —
a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).
IPSCIO Record ID: 25786
License Grant
Licensee received an exclusive worldwide license from the University. This includes the rights to sublicense and the intellectual property associated with SDX-101 and SDX-102, as well as issued patents and patent applications for several pre-clinical-stage projects, including the SDX-103 program.
License Property
SDX-101 is an oral compound which does not suppress the body’s immune system for the treatment of CLL. SDX-101 is an isomer, or component, of Lodine®, a marketed anti-inflammatory drug. The U.S. Food and Drug Administration, or FDA, has granted orphan drug status, a designation for drugs intended to treat a rare disease or condition affecting no more than 200,000 individuals in the U.S., for SDX-101 for the treatment of CLL.
SDX-102 is an intravenously administered small molecule which laboratory studies have shown kills tumors which cannot produce an important metabolic enzyme. Safety and tolerability data on SDX-102 were collected in clinical trials conducted at academic centers sponsored by the National Cancer Institute, or the NCI. These clinical trials tested the drug across a variety of cancers which are now known to produce this enzyme with a high frequency. The Licensee developed a proprietary, practical laboratory assay, or test, to identify patients whose cancers cannot produce this metabolic enzyme. In 2004, the Licensee was conducting Phase II trials of SDX-102 and are using their assay to select patients for these trials in difficult-to-treat cancers, including non-small cell lung cancer, or NSCLC, pancreatic and mesothelioma, none of which was previously studied by the NCI. The SDX-103 program involves analogs of the compound indanocine. Indanocine and indanocine analogs were synthesized and characterized at the University by the Licensee's founders. Indanocine displayed potent anti-proliferative activity when tested against a multitude of cancer cell lines at the NCI. These compounds differ from many clinically used drugs that block cell division in that they are active against multi-drug resistant cells and selectively kill non-dividing malignant cells. Anti-tumor activity of SDX-103 analogs has been observed in preliminary animal studies.
Field of Use
SDX-101 is covered by two use patents in the U.S. that prohibit third parties from using etodolac and etodolac analogs to treat CLL and NHL and R-etodolac and R-etodolac analogs to treat leukemias. These use patents expire in 2019. In the U.S. and selected foreign countries, the Licensee is pursuing additional use patents for etodolac, R-etodolac and etodolac analogs as well as composition of matter patents for etodolac analogs in the U.S. and in selected foreign countries. SDX-102 and assay methods were covered by two use patents in the U.S. that prohibit third parties from using an assay to measure MTAP status in a patient and then treating with an adenyl succinate synthetase inhibitor such as alanosine. These patents expired in 2013. SDX-102 is also covered by a patent in the U.S. that prohibits third parties from treating multiple drug resistance in MTAP-deleted tumors using an adenine synthesis inhibitor, such as l-alanosine. A patent application covering an assay method and monoclonal antibody for determining the presence or absence of MTAP is currently pending. Similar applications are being pursued or have issued in selected foreign countries.
IPSCIO Record ID: 5809
License Grant
The Company entered into a License Agreement wherein it obtained the Exclusive rights for the generic marker for Acute Myeloid Leukemia and intends to utilize these rights for the development of new diagnostic tools.
License Property
The new test is based on a recent discovery that mutations in a nucleophosmin (NPM1) gene are characteristic of 30-40% of the cases of AML. NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes.
Mutations in nucleophosmin NPM1 are the most frequent acquired molecular abnormalities in acute myeloid leukemia (AML).
Field of Use
Xenomics has obtained an exclusive license for the invention and developed a test that detects all 45 known mutations of NPM1 in a single reaction. The results will help physicians with prognosis, therapy, and monitoring of the disease.
IPSCIO Record ID: 306778
License Grant
Licensor (i) assigned to Licensee its patents/patent applications covering XP-102, known as BI 882370, a 2nd-generation pan-RAF inhibitor; and (ii) granted Licensee a worldwide, exclusive, royalty-bearing, and non-transferable license to all know-how controlled by Licensor or affiliates necessary for, or specifically related to, the discovery, development, manufacture, commercialization, or use of XP-102 and any family compound.
License Property
XP-102 is a second generation potent and selective pan-RAF inhibitor that binds to the DFG-out (inactive) conformation of the BRAF kinase. It is an oral small molecule drug candidate that is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.
Licensor focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology.
Field of Use
XP-102 for all human and non-human diagnostic, prophylactic, and therapeutic uses, including therapeutic uses targeting hematological and solid tumors. It is being developed for the potential treatment of colorectal cancer, melanoma, non-small cell lung cancer, hairy cell leukemia, and potentially other cancer types.
Licensee is a biopharmaceutical company that discovers and develops innovative small molecule drug candidates for the treatment of cancer in humans.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
